Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43857   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Efficacy and Safety of an Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence: A Placebo Controlled, Randomized, Double-blinded Parallel-Group Comparison for Superiority

    Summary
    EudraCT number
    2012-000341-13
    Trial protocol
    DE  
    Global end of trial date
    01 Jun 2015

    Results information
    Results version number
    v1(current)
    This version publication date
    11 Feb 2022
    First version publication date
    11 Feb 2022
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    OTV.PRE.01
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Weber & Weber GmbH & Co.KG
    Sponsor organisation address
    Herrschinger Strasse 33, Inning / Ammersee, Germany, 82266
    Public contact
    Preclinical & Clinical Trials, Weber&Weber, Weber & Weber GmbH & Co. KG, 49 81439270, zentrale@weber-weber.net
    Scientific contact
    Preclinical & Clinical Trials, Weber&Weber, Weber & Weber GmbH & Co. KG, 49 81439270, zentrale@weber-weber.net
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    17 Jun 2015
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    01 Jun 2015
    Global end of trial reached?
    Yes
    Global end of trial date
    01 Jun 2015
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To prove the superiority of Otovowen to placebo in the prevention of acute otitis media
    Protection of trial subjects
    Study was conducted in accordance with ICH GCP guidelines Study protocol, amendments, informed consent were approved by EC The investigator / designee informed the subjects of all aspects pertainig to the subject´s participation in the study
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    24 Sep 2013
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Germany: 311
    Worldwide total number of subjects
    311
    EEA total number of subjects
    311
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    311
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study was conducted in 30 centers (pediatric practitioners) in Germany. Patient cards were screened based on inclusion / exclusion criteria for eligible patients 1-2 months prior to study start. Study medication was administered at first signs of URI, observation period per subject was 6 months.

    Pre-assignment
    Screening details
    Children aged 12 to 59 months and with at least 3 episodes of acute otitis media (AOM) within 12 months prior to study inclusion as documented in their medical records.

    Period 1
    Period 1 title
    Double Blind Treatment Period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator
    Blinding implementation details
    Block randomization was done by computer and randomization lists were prepared. Based on the lists study drug (verum and placebo) were labeled with the appropriate randomization numbers.

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Otovoven
    Arm description
    Participants received Otovowen at first signs of URI until symptoms resolved
    Arm type
    Experimental

    Investigational medicinal product name
    Otovowen®
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Oral solution
    Routes of administration
    Oral use
    Dosage and administration details
    7 drops three times daily at first signs of URI until symptoms resolve (maximally 8 weeks of continuous application)

    Arm title
    Placebo
    Arm description
    Participants received placebo at first signs of URI until symptoms resolved
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Oral solution
    Routes of administration
    Oral use
    Dosage and administration details
    7 drops three times daily at first signs of URI until symptoms resolved (maximally 8 weeks of continuous application)

    Number of subjects in period 1
    Otovoven Placebo
    Started
    156
    155
    Completed
    156
    155

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Otovoven
    Reporting group description
    Participants received Otovowen at first signs of URI until symptoms resolved

    Reporting group title
    Placebo
    Reporting group description
    Participants received placebo at first signs of URI until symptoms resolved

    Reporting group values
    Otovoven Placebo Total
    Number of subjects
    156 155 311
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    156 155 311
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    0 0 0
        From 65-84 years
    0 0 0
        85 years and over
    0 0 0
        Otovowen
    0 0 0
    Gender categorical
    Units: Subjects
        Female
    75 67 142
        Male
    81 88 169

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Otovoven
    Reporting group description
    Participants received Otovowen at first signs of URI until symptoms resolved

    Reporting group title
    Placebo
    Reporting group description
    Participants received placebo at first signs of URI until symptoms resolved

    Primary: number of AOM episodes

    Close Top of page
    End point title
    number of AOM episodes
    End point description
    End point type
    Primary
    End point timeframe
    number of AOM episodes diagnosed by a physician within 6 months after enrolment per patient
    End point values
    Otovoven Placebo
    Number of subjects analysed
    156
    155
    Units: AOM episodes
        arithmetic mean (standard deviation)
    0.40 ± 0.66
    0.43 ± 0.77
    Statistical analysis title
    Statistical Analysis
    Comparison groups
    Placebo v Otovoven
    Number of subjects included in analysis
    311
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    ≤ 0.05
    Method
    Wilcoxon (Mann-Whitney)
    Confidence interval

    Secondary: Number of unscheduled visits due to AOM

    Close Top of page
    End point title
    Number of unscheduled visits due to AOM
    End point description
    End point type
    Secondary
    End point timeframe
    within 6 months
    End point values
    Otovoven Placebo
    Number of subjects analysed
    156
    155
    Units: visits
        arithmetic mean (standard deviation)
    0.42 ± 0.69
    0.52 ± 1.02
    No statistical analyses for this end point

    Secondary: Number of unscheduled visits due to URI

    Close Top of page
    End point title
    Number of unscheduled visits due to URI
    End point description
    End point type
    Secondary
    End point timeframe
    within 6 months
    End point values
    Otovoven Placebo
    Number of subjects analysed
    156
    155
    Units: visits
        arithmetic mean (standard deviation)
    2.16 ± 1.77
    1.96 ± 1.74
    No statistical analyses for this end point

    Secondary: Number of AOMs treated with antibiotics

    Close Top of page
    End point title
    Number of AOMs treated with antibiotics
    End point description
    End point type
    Secondary
    End point timeframe
    within 6 months
    End point values
    Otovoven Placebo
    Number of subjects analysed
    156
    155
    Units: AOM
        arithmetic mean (standard deviation)
    0.28 ± 0.57
    0.39 ± 0.75
    No statistical analyses for this end point

    Secondary: Number of URI treated with antibiotics

    Close Top of page
    End point title
    Number of URI treated with antibiotics
    End point description
    End point type
    Secondary
    End point timeframe
    within 6 months
    End point values
    Otovoven Placebo
    Number of subjects analysed
    156
    155
    Units: URI
        arithmetic mean (standard deviation)
    0.16 ± 0.43
    0.12 ± 0.33
    No statistical analyses for this end point

    Secondary: Number of days with URI

    Close Top of page
    End point title
    Number of days with URI
    End point description
    End point type
    Secondary
    End point timeframe
    within 6 months
    End point values
    Otovoven Placebo
    Number of subjects analysed
    156
    155
    Units: Days with URI
        arithmetic mean (standard deviation)
    41.0 ± 26.4
    39.7 ± 29.6
    No statistical analyses for this end point

    Secondary: Number of absent days from daycare

    Close Top of page
    End point title
    Number of absent days from daycare
    End point description
    End point type
    Secondary
    End point timeframe
    within 6 months
    End point values
    Otovoven Placebo
    Number of subjects analysed
    156
    155
    Units: days
        arithmetic mean (standard deviation)
    10.0 ± 8.0
    10.3 ± 9.2
    No statistical analyses for this end point

    Secondary: Number of absent days from work (parents/legal representative)

    Close Top of page
    End point title
    Number of absent days from work (parents/legal representative)
    End point description
    End point type
    Secondary
    End point timeframe
    within 6 months
    End point values
    Otovoven Placebo
    Number of subjects analysed
    156
    155
    Units: days
        arithmetic mean (standard deviation)
    5.0 ± 6.58
    4.9 ± 6.64
    No statistical analyses for this end point

    Secondary: Subjective evaluation of efficacy by patient/parent

    Close Top of page
    End point title
    Subjective evaluation of efficacy by patient/parent
    End point description
    End point type
    Secondary
    End point timeframe
    within 6 months
    End point values
    Otovoven Placebo
    Number of subjects analysed
    156
    155
    Units: Scale 0-3
        arithmetic mean (standard deviation)
    1.83 ± 0.95
    1.81 ± 0.98
    No statistical analyses for this end point

    Secondary: Subjective evaluation of tolerability by patient/parent

    Close Top of page
    End point title
    Subjective evaluation of tolerability by patient/parent
    End point description
    End point type
    Secondary
    End point timeframe
    within 6 months
    End point values
    Otovoven Placebo
    Number of subjects analysed
    156
    155
    Units: scale 0-3
        arithmetic mean (standard deviation)
    2.36 ± 0.62
    2.36 ± 0.60
    No statistical analyses for this end point

    Secondary: Mean number of AOMs plus suspicious ear disease

    Close Top of page
    End point title
    Mean number of AOMs plus suspicious ear disease
    End point description
    End point type
    Secondary
    End point timeframe
    within 6 months
    End point values
    Otovoven Placebo
    Number of subjects analysed
    156
    155
    Units: number
        arithmetic mean (standard deviation)
    0.56 ± 0.82
    0.57 ± 0.88
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    entire study
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    19
    Reporting groups
    Reporting group title
    Otovowen
    Reporting group description
    -

    Reporting group title
    Placebo
    Reporting group description
    -

    Serious adverse events
    Otovowen Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    8 / 152 (5.26%)
    3 / 150 (2.00%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Injury, poisoning and procedural complications
    concussion
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    febrile convulsion
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    vomiting
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    inguinal hernia
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    bronchopneumonia
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    acute tonsilitis
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    gastroenteritis
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    respiratory syncytial virus bronchiolitis
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    gastroenteritis norovirus
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Otovowen Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    128 / 152 (84.21%)
    130 / 150 (86.67%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    skin papilloma
         subjects affected / exposed
    1 / 152 (0.66%)
    3 / 150 (2.00%)
         occurrences all number
    1
    3
    Surgical and medical procedures
    Adenoidectomy
         subjects affected / exposed
    2 / 152 (1.32%)
    1 / 150 (0.67%)
         occurrences all number
    2
    1
    ear tube insertion
         subjects affected / exposed
    1 / 152 (0.66%)
    1 / 150 (0.67%)
         occurrences all number
    1
    1
    circumcision
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    myringotomy
         subjects affected / exposed
    2 / 152 (1.32%)
    0 / 150 (0.00%)
         occurrences all number
    2
    0
    General disorders and administration site conditions
    gait disorder
         subjects affected / exposed
    1 / 152 (0.66%)
    1 / 150 (0.67%)
         occurrences all number
    1
    1
    influenca like illness
         subjects affected / exposed
    34 / 152 (22.37%)
    44 / 150 (29.33%)
         occurrences all number
    51
    64
    pain
         subjects affected / exposed
    1 / 152 (0.66%)
    1 / 150 (0.67%)
         occurrences all number
    1
    1
    pyrexia
         subjects affected / exposed
    10 / 152 (6.58%)
    5 / 150 (3.33%)
         occurrences all number
    11
    6
    upper respiratory tract infection
         subjects affected / exposed
    1 / 152 (0.66%)
    1 / 150 (0.67%)
         occurrences all number
    1
    1
    local swelling
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    accidential device ingestion
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Immune system disorders
    allergic reaction to antibiotics
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    hypersensitivity
         subjects affected / exposed
    2 / 152 (1.32%)
    1 / 150 (0.67%)
         occurrences all number
    2
    1
    Reproductive system and breast disorders
    balanoposthitis
         subjects affected / exposed
    5 / 152 (3.29%)
    3 / 150 (2.00%)
         occurrences all number
    6
    4
    testicular retraction
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Respiratory, thoracic and mediastinal disorders
    asthma
         subjects affected / exposed
    2 / 152 (1.32%)
    6 / 150 (4.00%)
         occurrences all number
    2
    10
    cough
         subjects affected / exposed
    5 / 152 (3.29%)
    8 / 150 (5.33%)
         occurrences all number
    8
    11
    dyspnoea
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    epistaxis
         subjects affected / exposed
    0 / 152 (0.00%)
    2 / 150 (1.33%)
         occurrences all number
    0
    2
    bronchial hyperreactivity
         subjects affected / exposed
    1 / 152 (0.66%)
    5 / 150 (3.33%)
         occurrences all number
    2
    6
    allergic rhinitis
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    tonsillar hypertrophy
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Psychiatric disorders
    Agitation
         subjects affected / exposed
    1 / 152 (0.66%)
    1 / 150 (0.67%)
         occurrences all number
    1
    1
    attention seeking behaviour
         subjects affected / exposed
    1 / 152 (0.66%)
    1 / 150 (0.67%)
         occurrences all number
    1
    1
    encopresis
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    phonological disorder
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    sleep disorder
         subjects affected / exposed
    3 / 152 (1.97%)
    1 / 150 (0.67%)
         occurrences all number
    4
    1
    emotional disorders of childhood
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Investigations
    Cardiac murmur functional
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    skin test
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Injury, poisoning and procedural complications
    arthropod bite
         subjects affected / exposed
    3 / 152 (1.97%)
    1 / 150 (0.67%)
         occurrences all number
    3
    1
    laceration
         subjects affected / exposed
    9 / 152 (5.92%)
    4 / 150 (2.67%)
         occurrences all number
    9
    5
    splinter
         subjects affected / exposed
    1 / 152 (0.66%)
    2 / 150 (1.33%)
         occurrences all number
    1
    2
    mouth injury
         subjects affected / exposed
    1 / 152 (0.66%)
    1 / 150 (0.67%)
         occurrences all number
    1
    1
    face injury
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    contusion
         subjects affected / exposed
    2 / 152 (1.32%)
    2 / 150 (1.33%)
         occurrences all number
    2
    2
    brain contusion
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    joint injury
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    poisoning
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    periorbital contusion
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    eye contusion
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    humerus fracture
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    ligament injury
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    nail injury
         subjects affected / exposed
    2 / 152 (1.32%)
    0 / 150 (0.00%)
         occurrences all number
    2
    0
    exposure via eye contact
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Congenital, familial and genetic disorders
    Kidney duplex
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    phimosis
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Nervous system disorders
    speech disorder developmental
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    Blood and lymphatic system disorders
    Lympadenitis
         subjects affected / exposed
    0 / 152 (0.00%)
    2 / 150 (1.33%)
         occurrences all number
    0
    2
    leucocytosis
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Ear and labyrinth disorders
    ear pain
         subjects affected / exposed
    5 / 152 (3.29%)
    4 / 150 (2.67%)
         occurrences all number
    5
    5
    Tympanic membrane perforation
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    Tympanic membrane hyperaemia
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    Middle ear effusion
         subjects affected / exposed
    19 / 152 (12.50%)
    13 / 150 (8.67%)
         occurrences all number
    21
    14
    cerumen impaction
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Eye disorders
    conjunctivitis
         subjects affected / exposed
    32 / 152 (21.05%)
    25 / 150 (16.67%)
         occurrences all number
    41
    29
    visual impairment
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    Eye pain
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    excessive eye blinking
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Gastrointestinal disorders
    abdominal disomfort
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    abdominal distension
         subjects affected / exposed
    1 / 152 (0.66%)
    1 / 150 (0.67%)
         occurrences all number
    1
    1
    abdominal pain
         subjects affected / exposed
    9 / 152 (5.92%)
    4 / 150 (2.67%)
         occurrences all number
    9
    4
    anal fissure
         subjects affected / exposed
    0 / 152 (0.00%)
    2 / 150 (1.33%)
         occurrences all number
    0
    2
    aphthous stomatitis
         subjects affected / exposed
    2 / 152 (1.32%)
    2 / 150 (1.33%)
         occurrences all number
    2
    2
    constipation
         subjects affected / exposed
    6 / 152 (3.95%)
    11 / 150 (7.33%)
         occurrences all number
    7
    11
    diarrhea
         subjects affected / exposed
    11 / 152 (7.24%)
    6 / 150 (4.00%)
         occurrences all number
    12
    6
    dyspepsia
         subjects affected / exposed
    1 / 152 (0.66%)
    1 / 150 (0.67%)
         occurrences all number
    1
    1
    teething
         subjects affected / exposed
    0 / 152 (0.00%)
    4 / 150 (2.67%)
         occurrences all number
    0
    4
    vomiting
         subjects affected / exposed
    11 / 152 (7.24%)
    11 / 150 (7.33%)
         occurrences all number
    11
    11
    anal pruritus
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Skin and subcutaneous tissue disorders
    dermatitis
         subjects affected / exposed
    13 / 152 (8.55%)
    8 / 150 (5.33%)
         occurrences all number
    15
    9
    allergic dermatitis
         subjects affected / exposed
    1 / 152 (0.66%)
    2 / 150 (1.33%)
         occurrences all number
    1
    2
    dermatitis atopic
         subjects affected / exposed
    3 / 152 (1.97%)
    6 / 150 (4.00%)
         occurrences all number
    3
    7
    dermatitis diaper
         subjects affected / exposed
    4 / 152 (2.63%)
    4 / 150 (2.67%)
         occurrences all number
    4
    4
    rash
         subjects affected / exposed
    6 / 152 (3.95%)
    2 / 150 (1.33%)
         occurrences all number
    6
    2
    urticaria
         subjects affected / exposed
    4 / 152 (2.63%)
    2 / 150 (1.33%)
         occurrences all number
    4
    2
    photosensivity reaction
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    xeroderma
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Renal and urinary disorders
    enuresis
         subjects affected / exposed
    3 / 152 (1.97%)
    2 / 150 (1.33%)
         occurrences all number
    3
    2
    urinary retention
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    dysuria
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Musculoskeletal and connective tissue disorders
    bone pain
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    foot deformity
         subjects affected / exposed
    2 / 152 (1.32%)
    1 / 150 (0.67%)
         occurrences all number
    2
    1
    back pain
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Infections and infestations
    acute tonsillitis
         subjects affected / exposed
    7 / 152 (4.61%)
    9 / 150 (6.00%)
         occurrences all number
    7
    12
    bronchitis
         subjects affected / exposed
    32 / 152 (21.05%)
    39 / 150 (26.00%)
         occurrences all number
    51
    55
    bronchopneumonia
         subjects affected / exposed
    3 / 152 (1.97%)
    6 / 150 (4.00%)
         occurrences all number
    3
    8
    candida nappy rash
         subjects affected / exposed
    2 / 152 (1.32%)
    4 / 150 (2.67%)
         occurrences all number
    3
    4
    enterobiasis
         subjects affected / exposed
    0 / 152 (0.00%)
    3 / 150 (2.00%)
         occurrences all number
    0
    3
    Epstein-Barr virus infection
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    erythema infectiosum
         subjects affected / exposed
    4 / 152 (2.63%)
    3 / 150 (2.00%)
         occurrences all number
    4
    3
    exanthema subitum
         subjects affected / exposed
    1 / 152 (0.66%)
    1 / 150 (0.67%)
         occurrences all number
    1
    1
    gastroenteritis
         subjects affected / exposed
    31 / 152 (20.39%)
    31 / 150 (20.67%)
         occurrences all number
    36
    36
    hand-foot-and-mouth disease
         subjects affected / exposed
    3 / 152 (1.97%)
    5 / 150 (3.33%)
         occurrences all number
    3
    6
    impetigo
         subjects affected / exposed
    1 / 152 (0.66%)
    2 / 150 (1.33%)
         occurrences all number
    1
    2
    laryngitis
         subjects affected / exposed
    3 / 152 (1.97%)
    9 / 150 (6.00%)
         occurrences all number
    4
    10
    laryngotracheitis obstructive
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    lice infestation
         subjects affected / exposed
    1 / 152 (0.66%)
    2 / 150 (1.33%)
         occurrences all number
    1
    2
    Molluscum contagiosum
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    mumps
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    nasopharyngitis
         subjects affected / exposed
    1 / 152 (0.66%)
    1 / 150 (0.67%)
         occurrences all number
    1
    1
    oral candidiasis
         subjects affected / exposed
    1 / 152 (0.66%)
    1 / 150 (0.67%)
         occurrences all number
    1
    1
    paronchya
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    parotitis
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    pharyngitis
         subjects affected / exposed
    8 / 152 (5.26%)
    9 / 150 (6.00%)
         occurrences all number
    8
    9
    pharyngitis streptococcal
         subjects affected / exposed
    1 / 152 (0.66%)
    4 / 150 (2.67%)
         occurrences all number
    1
    4
    pneumonia
         subjects affected / exposed
    4 / 152 (2.63%)
    1 / 150 (0.67%)
         occurrences all number
    5
    1
    pyelonephritis
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    rhinitis
         subjects affected / exposed
    1 / 152 (0.66%)
    1 / 150 (0.67%)
         occurrences all number
    1
    1
    scarlet fever
         subjects affected / exposed
    4 / 152 (2.63%)
    10 / 150 (6.67%)
         occurrences all number
    4
    11
    sinusitis
         subjects affected / exposed
    1 / 152 (0.66%)
    3 / 150 (2.00%)
         occurrences all number
    1
    3
    tonsillitis streptococcal
         subjects affected / exposed
    0 / 152 (0.00%)
    2 / 150 (1.33%)
         occurrences all number
    0
    2
    urinary tract infection
         subjects affected / exposed
    2 / 152 (1.32%)
    3 / 150 (2.00%)
         occurrences all number
    2
    3
    varicella
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    2
    viral rash
         subjects affected / exposed
    3 / 152 (1.97%)
    2 / 150 (1.33%)
         occurrences all number
    3
    2
    skin candida
         subjects affected / exposed
    1 / 152 (0.66%)
    3 / 150 (2.00%)
         occurrences all number
    1
    3
    mycoplasma infection
         subjects affected / exposed
    1 / 152 (0.66%)
    1 / 150 (0.67%)
         occurrences all number
    1
    1
    streptococcal infection
         subjects affected / exposed
    2 / 152 (1.32%)
    3 / 150 (2.00%)
         occurrences all number
    2
    3
    bronchitis, bacterial
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    oral herpes
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    gastroenteritis viral
         subjects affected / exposed
    0 / 152 (0.00%)
    1 / 150 (0.67%)
         occurrences all number
    0
    1
    herpangina
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    hordeolum
         subjects affected / exposed
    3 / 152 (1.97%)
    0 / 150 (0.00%)
         occurrences all number
    3
    0
    infection susceptibility increased
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    otitis externa
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    pertussis
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    vulvitis
         subjects affected / exposed
    2 / 152 (1.32%)
    0 / 150 (0.00%)
         occurrences all number
    2
    0
    rhinotracheitis
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    staphylococcus skin infection
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    superinfection bacterial
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0
    Metabolism and nutrition disorders
    iron deficiency
         subjects affected / exposed
    1 / 152 (0.66%)
    0 / 150 (0.00%)
         occurrences all number
    1
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    03 Jun 2013
    - The upper age limit in the inclusion criteria was raised from 35 to 59 months. - The required number of AOMs in the last year was reduced from 4 to 3 (starting from 01.10.2012). - Study duration was decreased from 12 to 6 months. All patients will be included in the period from 01.10. to 31.10.2013. The study will end for all patients after 6 months i.e. between 01 and 30 April 2014. - The list of not allowed concomitant therapies has been reduced and simplified; not allowed are now only herbal and homeopathic remedies with secretolytic, anti-inflammatory and immunostimulatory effects. - Suitable patients are identified and approached in advance through screening of the patient file - The14-day telephone interviews are eliminated. Instead, parents complete an online diary at weekly intervals. - The investigator completes documentation in an electronic CRF, rather than a paper version. - A power of attorney for study consent is created by a parent/custodian.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Children at inclusion were most likely not as prone to AOM as suspected or AOMs assessed during the 12 months prior to randomization were not diagnosed according to the strict criteria as specified in the study protocol for the study period
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 02:24:16 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA